Search research articles
Contact Us
Filters
Showing results (51-60 of 82) with videos related to
Page
of 9
Sort By:
European Urology Oncology
|
August 15, 2019
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy
Karl Patterson, Vimalanand Prabhu, Ruifeng Xu, et al.
The Journal of Biological Chemistry
|
May 3, 2020
Correction: Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system
Michael T Werner, Hongxin Wang, Nicole Hamagami, et al.
Nano Letters
|
March 21, 2023
STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2
Yuebao Zhang, Jingyue Yan, Xucheng Hou, et al.
Nano Research
|
August 1, 2025
LPA<sub>1</sub> antagonist-derived LNPs deliver A20 mRNA and promote anti-fibrotic activities
Jingyue Yan, Diana D Kang, Chang Wang, et al.
JAMA Dermatology
|
December 20, 2023
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial
Kim A Papp, Kenneth Gordon, Bruce Strober, et al.
Science Advances
|
August 13, 2025
Lipid nanoparticles for mRNA delivery in brain via systemic administration
Dinglingge Cao, Xucheng Hou, Chang Wang, et al.
Proteins
|
April 9, 2019
The uncharacterized bacterial protein YejG has the same architecture as domain III of elongation factor G
Biswaranjan Mohanty, Paulina Hanson-Manful, Thomas J Finn, et al.
Current Medical Research and Opinion
|
July 23, 2020
Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
Arielle G Bensimon, Yichen Zhong, Umang Swami, et al.
Dermatology and Therapy
|
July 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
April W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Dermatology and Therapy
|
March 6, 2025
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
April W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 82) with videos related to
Sort By:
Page
of 9
European Urology Oncology
|
August 15, 2019
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy
Karl Patterson, Vimalanand Prabhu, Ruifeng Xu, et al.
The Journal of Biological Chemistry
|
May 3, 2020
Correction: Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system
Michael T Werner, Hongxin Wang, Nicole Hamagami, et al.
Nano Letters
|
March 21, 2023
STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2
Yuebao Zhang, Jingyue Yan, Xucheng Hou, et al.
Nano Research
|
August 1, 2025
LPA<sub>1</sub> antagonist-derived LNPs deliver A20 mRNA and promote anti-fibrotic activities
Jingyue Yan, Diana D Kang, Chang Wang, et al.
JAMA Dermatology
|
December 20, 2023
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial
Kim A Papp, Kenneth Gordon, Bruce Strober, et al.
Science Advances
|
August 13, 2025
Lipid nanoparticles for mRNA delivery in brain via systemic administration
Dinglingge Cao, Xucheng Hou, Chang Wang, et al.
Proteins
|
April 9, 2019
The uncharacterized bacterial protein YejG has the same architecture as domain III of elongation factor G
Biswaranjan Mohanty, Paulina Hanson-Manful, Thomas J Finn, et al.
Current Medical Research and Opinion
|
July 23, 2020
Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
Arielle G Bensimon, Yichen Zhong, Umang Swami, et al.
Dermatology and Therapy
|
July 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
April W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Dermatology and Therapy
|
March 6, 2025
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
April W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Page
of 9